Poxel SA

Poxel SA has a market capitalization of EUR 13.68 million, with a market price of EUR 0.255 per share and 53.66 million shares outstanding. The company has no disclosed liquidity metrics, and its balance sheet is not available, making it impossible to assess liquidity risk. The company's revenue of EUR 5.01 million is significantly below the median for its industry, and it has not disclosed profitability metrics such as net income or EBITDA. As a pre-revenue biopharmaceutical firm, Poxel's valuation is based on clinical progress and pipeline potential rather than traditional profitability metrics. Poxel's operations are concentrated in the biopharmaceutical sector, with no disclosed geographic revenue breakdown. The company's lead product, Imeglimin, is in clinical phase 2 for Type 2 diabetes, and it has a preclinical pipeline targeting metabolic diseases. The company's outlook for the current fiscal year is uncertain due to the absence of revenue growth data. Poxel's recent revenue of EUR 1.98 million is a fraction of its reported EUR 5.01 million, indicating potential volatility or one-time events. Poxel's risk assessment indicates low dilution risk, but liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in source documents. The company has not disclosed any recent events such as filings or transcripts that would provide insight into its operational or strategic developments.